Ian M Gralnek1, Peter D Siersema2, Zamir Halpern3, Ori Segol4, Alaa Melhem3, Alain Suissa5, Erwin Santo3, Alan Sloyer6, Jay Fenster7, Leon M G Moons2, Vincent K Dik2, Ralph B D'Agostino8, Douglas K Rex9. 1. Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Gastrointestinal Endoscopy Unit, Elisha Hospital, Haifa, Israel. Electronic address: i_gralnek@rambam.health.gov.il. 2. Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Netherlands. 3. Department of Gastroenterology, Tel Aviv Sourasky Medical Centre and Tel Aviv University School of Medicine, Tel Aviv, Israel. 4. Lady Davis Carmel Medical Centre, Haifa, Israel. 5. Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel; Gastrointestinal Endoscopy Unit, Elisha Hospital, Haifa, Israel. 6. North Shore Gastroenterology Associates, Great Neck, NY, USA. 7. South Shore Gastroenterology, Cedarhurst, NY, USA. 8. Wake Forest University School of Medicine, Winston-Salem, NC, USA. 9. Indiana University Hospital, Indianapolis, IN, USA.
Abstract
BACKGROUND: Although colonoscopy is the accepted standard for detection of colorectal adenomas and cancers, many adenomas and some cancers are missed. To avoid interval colorectal cancer, the adenoma miss rate of colonoscopy needs to be reduced by improvement of colonoscopy technique and imaging capability. We aimed to compare the adenoma miss rates of full-spectrum endoscopy colonoscopy with those of standard forward-viewing colonoscopy. METHODS: We did an international, multicentre, randomised trial at three sites in Israel, one site in the Netherlands, and two sites in the USA between Feb 1, 2012, and March 31, 2013. Patients aged 18-70 years referred for colorectal cancer screening, polyp surveillance, ordiagnostic assessment underwent same-day, back-to-back tandem colonoscopy with standard forward-viewing colonoscope and the full-spectrum endoscopy colonoscope. The patients were randomly assigned (1:1), via computer-generated randomisation with block size of 20, to which procedure was done first. The endoscopist was masked to group allocation until immediately before the start of colonoscopy examinations; patients were not masked. The primary endpoint was adenoma miss rates. We did per-protocol analyses. This trial is registered with ClinicalTrials.gov, number NCT01549535. FINDINGS:197 participants were enrolled. 185 participants were included in the per-protocol analyses: 88 (48%) were randomly assigned to receive standard forward-viewing colonoscopy first, and 97 (52%) to receive full-spectrum endoscopy colonoscopy first. By per-lesion analysis, the adenoma miss rate was significantly lower in patients in the full-spectrum endoscopy group than in those in the standard forward-viewing procedure group: five (7%) of 67 vs 20 (41%) of 49 adenomas were missed (p<0·0001). Standard forward-viewing colonoscopy missed 20 adenomas in 15 patients; of those, three (15%) were advanced adenomas. Full-spectrum endoscopy missed five adenomas in five patients in whom an adenoma had already been detected with first-pass standard forward-viewing colonoscopy; none of these missed adenomas were advanced. One patient was admitted to hospital for colitis detected at colonoscopy, whereas five minor adverse events were reported including vomiting, diarrhoea, cystitis, gastroenteritis, and bleeding. INTERPRETATION: Full-spectrum endoscopy represents a technology advancement for colonoscopy and could improve the efficacy of colorectal cancer screening and surveillance. FUNDING: EndoChoice.
RCT Entities:
BACKGROUND: Although colonoscopy is the accepted standard for detection of colorectal adenomas and cancers, many adenomas and some cancers are missed. To avoid interval colorectal cancer, the adenoma miss rate of colonoscopy needs to be reduced by improvement of colonoscopy technique and imaging capability. We aimed to compare the adenoma miss rates of full-spectrum endoscopy colonoscopy with those of standard forward-viewing colonoscopy. METHODS: We did an international, multicentre, randomised trial at three sites in Israel, one site in the Netherlands, and two sites in the USA between Feb 1, 2012, and March 31, 2013. Patients aged 18-70 years referred for colorectal cancer screening, polyp surveillance, or diagnostic assessment underwent same-day, back-to-back tandem colonoscopy with standard forward-viewing colonoscope and the full-spectrum endoscopy colonoscope. The patients were randomly assigned (1:1), via computer-generated randomisation with block size of 20, to which procedure was done first. The endoscopist was masked to group allocation until immediately before the start of colonoscopy examinations; patients were not masked. The primary endpoint was adenoma miss rates. We did per-protocol analyses. This trial is registered with ClinicalTrials.gov, number NCT01549535. FINDINGS: 197 participants were enrolled. 185 participants were included in the per-protocol analyses: 88 (48%) were randomly assigned to receive standard forward-viewing colonoscopy first, and 97 (52%) to receive full-spectrum endoscopy colonoscopy first. By per-lesion analysis, the adenoma miss rate was significantly lower in patients in the full-spectrum endoscopy group than in those in the standard forward-viewing procedure group: five (7%) of 67 vs 20 (41%) of 49 adenomas were missed (p<0·0001). Standard forward-viewing colonoscopy missed 20 adenomas in 15 patients; of those, three (15%) were advanced adenomas. Full-spectrum endoscopy missed five adenomas in five patients in whom an adenoma had already been detected with first-pass standard forward-viewing colonoscopy; none of these missed adenomas were advanced. One patient was admitted to hospital for colitis detected at colonoscopy, whereas five minor adverse events were reported including vomiting, diarrhoea, cystitis, gastroenteritis, and bleeding. INTERPRETATION: Full-spectrum endoscopy represents a technology advancement for colonoscopy and could improve the efficacy of colorectal cancer screening and surveillance. FUNDING: EndoChoice.
Authors: Douglas K Rex; John L Petrini; Todd H Baron; Amitabh Chak; Jonathan Cohen; Stephen E Deal; Brenda Hoffman; Brian C Jacobson; Klaus Mergener; Bret T Petersen; Michael A Safdi; Douglas O Faigel; Irving M Pike Journal: Gastrointest Endosc Date: 2006-04 Impact factor: 9.427
Authors: Jeroen C van Rijn; Johannes B Reitsma; Jaap Stoker; Patrick M Bossuyt; Sander J van Deventer; Evelien Dekker Journal: Am J Gastroenterol Date: 2006-02 Impact factor: 10.864
Authors: D K Rex; C S Cutler; G T Lemmel; E Y Rahmani; D W Clark; D J Helper; G A Lehman; D G Mark Journal: Gastroenterology Date: 1997-01 Impact factor: 22.682
Authors: Robert L Barclay; Joseph J Vicari; Andrea S Doughty; John F Johanson; Roger L Greenlaw Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck Journal: Ann Intern Med Date: 2008-12-15 Impact factor: 25.391
Authors: Jaroslaw Regula; Maciej Rupinski; Ewa Kraszewska; Marcin Polkowski; Jacek Pachlewski; Janina Orlowska; Marek P Nowacki; Eugeniusz Butruk Journal: N Engl J Med Date: 2006-11-02 Impact factor: 91.245
Authors: D Heresbach; T Barrioz; M G Lapalus; D Coumaros; P Bauret; P Potier; D Sautereau; C Boustière; J C Grimaud; C Barthélémy; J Sée; I Serraj; P N D'Halluin; B Branger; T Ponchon Journal: Endoscopy Date: 2008-04 Impact factor: 10.093
Authors: Perry J Pickhardt; Pamela A Nugent; Pauline A Mysliwiec; J Richard Choi; William R Schindler Journal: Ann Intern Med Date: 2004-09-07 Impact factor: 25.391
Authors: Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka Journal: Gastroenterology Date: 2015-11-24 Impact factor: 22.682
Authors: Luiz Ronaldo Alberti; Diego Paim Carvalho Garcia; Debora Lucciola Coelho; David Correa Alves De Lima; Andy Petroianu Journal: World J Gastrointest Oncol Date: 2015-12-15